|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
1.03 Billion
|
|
CAGR (2025-2030)
|
5.28%
|
|
Fastest Growing Segment
|
Instruments
|
|
Largest Market
|
Midwest
|
|
Market Size (2030)
|
USD 1.39 Billion
|
Market Overview
United States Multiomics Market was
valued at USD 1.03 Billion in 2024 and is expected to reach USD 1.39 Billion by
2030 with a CAGR of 5.28%. Multiomics integrates data from multiple molecular
layers to offer a more holistic view of health, disease, and drug response,
making it a powerful tool in precision medicine, drug discovery, and clinical
diagnostics. In the U.S., this market is expanding due to strong investment in
life sciences research, increasing adoption of personalized healthcare, and the
availability of advanced technological platforms.
Academic institutions, biotechnology
firms, and pharmaceutical companies are leveraging multiomics to uncover
complex disease mechanisms, identify novel biomarkers, and develop more
targeted therapies. Despite its potential, the U.S. multiomics market faces
challenges, particularly in terms of data integration, standardization, and
interpretation. Managing large, complex datasets across different omics
platforms requires robust bioinformatics capabilities and advanced
computational infrastructure. There is also a growing need for skilled
professionals who can bridge the gap between molecular biology and data
science.
Key Market Drivers
Growth
in Healthcare Industry
The growth of the healthcare industry in the United
States is a major driver of the expanding multiomics market. In 2023, U.S.
healthcare expenditures increased by 7.5%, reaching a total of USD 4.9
trillion, equivalent to approximately USD 14,570 per capita. This spending
represented 17.6% of the country’s Gross Domestic Product (GDP). As the
sector shifts toward precision medicine and data-driven care, the demand for
comprehensive, multi-layered biological analysis has surged. Multiomics, an
integrated approach that combines genomics, proteomics, transcriptomics,
metabolomics, and other “omics” technologies is increasingly seen as essential
to understanding complex diseases and tailoring more effective treatments.
One of the most significant factors fueling this
demand is the healthcare industry’s emphasis on personalized medicine. For
instance, USP, headquartered in Maryland, is committed to ensuring a reliable
and consistent supply of safe, high-quality medicines. Leveraging scientific
expertise and capacity-building solutions, USP develops standards, practical
tools, and resources that empower healthcare professionals to deliver optimal
personalized care across all healthcare environments. With a growing focus
on treatments that are customized to an individual’s unique biological profile,
healthcare providers and researchers are turning to multiomics to uncover
deeper molecular insights.
Surge
in Technological Advancements
The surge in technological advancements is a primary
driver of growth in the United States multiomics market. Breakthroughs in
high-throughput sequencing, mass spectrometry, and bioinformatics have enabled
comprehensive and simultaneous analysis of genomics, proteomics, metabolomics,
and other omics data. These innovations have significantly enhanced data
accuracy, processing speed, and integration capabilities, facilitating deeper
insights into complex biological systems and disease mechanisms.
Furthermore, the integration of artificial
intelligence and machine learning algorithms is accelerating the interpretation
of multiomics datasets, enabling personalized medicine and targeted therapeutic
development. AI techniques have become essential in addressing these
challenges, enabling researchers to effectively manage the high dimensionality
and heterogeneity of multi-omics data. This approach not only reveals
previously hidden patterns but also enhances the prediction of biological
outcomes, thereby accelerating biomedical research and advancing the
development of personalized medicine. The development of advanced platforms
and automation technologies is also reducing costs and increasing scalability,
making multiomics approaches more accessible to research institutions and
pharmaceutical companies.
Download Free Sample Report
Key Market Challenges
Asymptomatic
Nature of HSV Infections
The asymptomatic nature of HSV
infections presents a unique challenge for the United States multiomics market,
particularly in efforts to develop diagnostic tools and personalized treatment
strategies. Since a significant proportion of individuals infected with Herpes
Simplex Virus do not exhibit noticeable symptoms, detecting and studying the
virus becomes inherently difficult. This silent transmission complicates sample
collection and patient identification, which are critical for generating
meaningful multiomics data.
In multiomics research, comprehensive
biological data from infected individuals is essential to understand the
molecular mechanisms of infection, immune response, and viral latency. However,
the asymptomatic presentation often results in underdiagnosis and
underreporting, limiting the availability of well-characterized clinical
samples. This scarcity hampers the ability to identify reliable biomarkers or
molecular signatures associated with different stages of HSV infection.
Key Market Trends
Expansion
of Home Testing
The expansion of home testing is an
emerging trend significantly influencing the United States multiomics market. For
instance, at-home over-the-counter (OTC) COVID-19 diagnostic tests can
determine the presence of an active COVID-19 infection. These tests are
FDA-authorized for self-administration without a prescription, either at home
or in other non-clinical settings. As consumers increasingly seek
convenient, accessible, and personalized healthcare solutions, the integration
of multiomics technologies into home-based testing platforms is gaining
momentum. This trend aligns with the broader shift toward patient-centric care
and digital health innovation within the U.S. healthcare landscape.
Home testing powered by multiomics
enables individuals to gain comprehensive insights into their genetic,
proteomic, and metabolic profiles without the need for frequent clinical
visits. Advances in sample collection methods, such as minimally invasive kits
for saliva, blood, or urine, combined with robust analytical technologies, have
made it feasible to perform complex multiomic analyses outside traditional
laboratory settings. This accessibility enhances early disease detection,
wellness monitoring, and personalized health management directly in the
consumer’s home.
Segmental Insights
Product
& Service Insights
Based on Product & Service, Instruments
have emerged as the fastest growing segment in the United States Multiomics
Market in 2024. This is due to increasing demand for advanced analytical
technologies essential for high-throughput and precise multiomics data
generation. Innovations in mass spectrometry, next-generation sequencing
platforms, chromatography systems, and microarray technologies are driving
growth by enabling researchers to conduct comprehensive analyses of genomics,
proteomics, metabolomics, and other omics layers with higher accuracy and
efficiency.
Platform
Insights
Based on Platform, Genomics have emerged
as the fastest growing segment in the United States Multiomics Market during
the forecast period. This is due to its critical role in advancing personalized
medicine and precision healthcare. The ability to analyze an individual’s
genetic makeup enables more accurate disease diagnosis, targeted treatment
plans, and improved patient outcomes. Technological advancements such as
next-generation sequencing (NGS) have significantly reduced costs and
turnaround times, making genomic analysis more accessible to research
institutions and clinical laboratories.
Download Free Sample Report
Regional Insights
Based on Region, Midwest have emerged as
the dominating region in the United States Multiomics Market in 2024. This is due
to a combination of strong research infrastructure, a robust biotechnology
ecosystem, and strategic investments in advanced life sciences technologies.
The region is home to several leading universities, research institutions, and
biopharmaceutical companies that drive innovation in genomics, proteomics,
metabolomics, and other omics disciplines. This concentration of expertise
fosters collaboration and accelerates the development and application of
multiomics technologies.
Recent Development
- In February 2025, Illumina, Inc.
announced a series of strategic roadmap innovations, introducing the industry’s
most comprehensive portfolio of omics solutions and sequencing applications.
Covering a broad range of technologies including genomics, spatial
transcriptomics, single-cell analysis, CRISPR, epigenetics, and advanced data
analytics software these solutions are designed to empower researchers with
deeper insights into the underlying drivers of disease. Built on Illumina’s
industry-leading sequencing platforms, the new offerings set a new benchmark
for scale, accuracy, and reliability.
- In January 2025, Enhanc3D Genomics, a leader in 3D
genomics technology, announced the launch of a comprehensive suite of
integrated multi-omics solutions designed to accelerate and enhance the
precision of drug discovery. Built on the company’s proprietary 3D genomics
platform and enriched by advanced multi-omics analysis, the new 3D Multi-omic
offerings deliver a robust end-to-end solution that supports data-driven
decision-making across all stages of the drug discovery and development
lifecycle. The platform leverages patented Promoter Capture Hi-C technology to
generate high-resolution, genome-wide regulatory maps across any cell type,
subtype, or state, by identifying interactions between promoters and regulatory
regions.
- In May 2025, Illumina, Inc. and Ovation.io, Inc., a
company focused on developing high-quality multiomics datasets announced the
creation of the largest commercially available clinical multiomic dataset
derived from 25,000 patients treated with GLP-1 receptor agonist therapies.
This dataset will be made accessible to the pharmaceutical industry to support
and accelerate drug discovery and development efforts. The collaboration marks
the latest in a series of strategic partnerships aimed at leveraging multimodal
data to drive deeper biological insights and advance innovation across the
healthcare ecosystem.
- In January 2024, Bio-Techne Corporation announced that
its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD), will
introduce the industry’s first fully automated spatial multiomics workflow
capable of same-section hyperplex detection of both RNA and protein biomarkers.
This cutting-edge solution represents a significant advancement in predictive
biomarker research and drug development. The platform combines ACD’s RNAscope
HiPlex RNA detection technology with Lunaphore’s universal multiplex sequential
immunofluorescence (seqIF) on the COMET system, enabling high-precision protein
detection using standard, non-conjugated antibodies.
Key Market Players
- Becton,
Dickinson and Company
- Thermo
Fisher Scientific Inc.
- Illumina,
Inc
- Danaher
Corporation
- PerkinElmer
Inc.
- Shimadzu
Corporation
- Bruker
Corporation
- Agilent
Technologies, Inc.
|
By Product & Service
|
By Platform
|
By Region
|
- Instruments
- Consumables
- Software
- Services
|
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
|
- Northeast
- Midwest
- South
- West
|
Report Scope
In this report, the United States Multiomics Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- United States Multiomics
Market, By
Product & Service:
o Instruments
o Consumables
o Software
o Services
- United States Multiomics
Market, By
Platform:
o Genomics
o Transcriptomics
o Proteomics
o Metabolomics
o Integrated Omics Platforms
- United States Multiomics
Market, By Region:
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the United States Multiomics Market.
Available Customizations:
United States Multiomics Market report with the
given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
United States Multiomics
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]